CytomX Therapeutics Inc

CTMX is showing early Stage 1 repair after the mid-June low, confirmed by a Bullish Pivot Point pattern and stacked short-term EMAs; medium-term bias shifts bullish, and execution on holds above the EMA9/20 support is warranted.

• ↑Phase 1 shows 32% ORR at 10 mg/kg, 20% at 8.6 mg/kg and 94% DCR.
• ↑93 patients enrolled, indicating strong trial momentum.
• ↓Revenue fell to $6 M from $33.4 M after BMS collaboration ended.